A case study of a large rheumatoid arthritis patient population analyzed the frequency of serious adverse events in patients using TCZ (65,000 patient-years) in comparison to anti-TNFα (50,000 patient-years) therapies. This evidence concerns the gene TNF and rheumatoid arthritis.